MK-8591 (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture | Zendy

Vincent H. Wu | Zendy; Robert A. Smith | Zendy; Sara Masoum | Zendy; Da. Raugi | Zendy; Selly Ba | Zendy; Moussa Seydi | Zendy; Jay A. Grobler | Zendy; Geoffrey S. Gottlieb | Zendy

Open Access

MK-8591 (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture

Author(s) -

Vincent H. Wu,

Robert A. Smith,

Sara Masoum,

Da. Raugi,

Selly Ba,

Moussa Seydi,

Jay A. Grobler,

Geoffrey S. Gottlieb

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00744-17

Subject(s) - deoxyadenosine , human immunodeficiency virus (hiv) , mutant , virology , drug , biology , chemistry , medicine , pharmacology , biochemistry , enzyme , gene

There is a pressing need to identify more effective antiretroviral drugs for HIV-2 treatment. Here, we show that the investigational compound MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine [EFdA]) is highly active against group A and B isolates of HIV-2; 50% effective concentrations [EC 50 ] for HIV-2 were, on average, 4.8-fold lower than those observed for HIV-1. MK-8591 also retains potent activity against multinucleoside-resistant HIV-2 mutants (EC 50 ≤ 11 nM). These data suggest that MK-8591 may have antiviral activity in HIV-2-infected individuals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research